Hear about Genetic Signatures EasyScreen™ Kits at the upcoming NRL Workshop on Molecular Diagnostics

Genetic Signatures EasyScreen™ Pathogen Detection Kits will be featured in two oral presentations at the upcoming NRL Workshop on Molecular Diagnostics in Melbourne, Australia.

The NRL Molecular Workshop is a forum for scientists, regulators, test kit manufacturers and clinicians to unite and discuss current issues and new technologies occurring in the world of molecular pathology for infectious diseases. The aim of this workshop is to focus specifically on molecular techniques involved in detecting infectious pathogens.

The first presentation titled “Impact of automation in the diagnostic laboratory” will be given by Tony Field from Australian Clinical Labs and the second presentation, entitled “Evaluation of a new 3base™ Assay for Screening of Sexually Transmitted Infections” will be given by Dr. Damien Stark of St. Vincent’s hospital.

Click here to visit the conference website for more information

 


About NRL: NRL was established in 1985 as part of the Australian Government’s HIV/AIDS Strategy, to evaluate HIV tests and adjudicate on the interpretation of HIV test results.  Today, NRL remains a not-for-profit scientific organisation that exists for the benefit of the public.  Its overall goal is to support laboratories, in Australia and internationally, that perform testing for the diagnosis and management of human infectious disease. NRL is designated a WHO Collaborating Centre for Diagnostics and Laboratory Support for HIV and AIDS and Other Blood-borne Infections.

 

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3Base™. Founded in 2001 by the late Dr Geoffrey Grigg, the former Chief of Molecular Biology at CSIRO, Genetic Signatures has released a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. MDx is a modern technique increasingly used by hospitals and pathology laboratories to detect specific sequences of the genome, the DNA or RNA that define an organism. Genetic Signatures’ proprietary MDx 3Base™ platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening. As the spread of infectious diseases around the world continues to grow, the Company plans to launch additional products for the detection of pathogens associated with MRSA, sexual health infections, tuberculosis, meningitis and, antibiotic resistance.